Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research

3722 - Impact of blood-based biomarkers on survival outcomes with pembrolizumab in pre-treated advanced non-small cell lung cancer (NSCLC) patients (pts).

Date

20 Oct 2018

Session

Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research

Topics

Targeted Therapy;  Immunotherapy

Tumour Site

Presenters

Rebecca Tay

Citation

Annals of Oncology (2018) 29 (suppl_8): viii493-viii547. 10.1093/annonc/mdy292

Authors

R.Y. Tay, J. Chiramel, E. Montague, F. Wilson, Y. Summers, F.H. Blackhall, R. Califano

Author affiliations

  • Department Of Medical Oncology, The Christie NHS Foundation Trust, M20 4BX - Manchester/GB
More

Resources

Abstract 3722

Background

Elevated neutrophil-lymphocyte ratio (NLR), derived NLR (dNLR) and lactate dehydrogenase (LDH) have been identified as potential prognostic/predictive biomarkers to immune checkpoint inhibitors (ICI). The Lung Immune Prognostic Index (LIPI) utilises dNLR and LDH to define prognostic subgroups associated with overall survival (OS) and overall response rate (ORR) to ICI. The objective of this study was to assess progression free survival (PFS) and OS in pre-treated advanced NSCLC pts who received pembrolizumab and to perform a comparative analysis of pre-treatment NLR, dNLR, LDH, LIPI score and PD-L1 tumour proportion score (TPS) on survival, ORR and toxicity.

Methods

Pre-treated advanced NSCLC pts who received pembrolizumab (Jan ’17-Jan ’18) at The Christie were identified. Baseline demographics, PD-L1 TPS, NLR, dNLR and LDH were collected. Elevated NLR, dNLR and LDH was defined as ≥ 5, ≥3 and ≥ upper limit normal (ULN), respectively. LIPI score was calculated (Table). Survival analysis was performed using Kaplan-Meier method. Univariate logistic regression models were used to assess patient characteristics on PFS.Table: 1462P

Lung immune prognostic index (LIPI)

GooddNLR <3 AND LDH
IntermediatedNLR ≥3 OR LDH ≥ULN
PoordNLR ≥3 AND LDH ≥ULN

Results

58 pts were analysed; median age: 67, males 66%, non-squamous 64%, 53% had PD-L1 TPS 1-49%. After median follow up of 5.2 months, 38/58 (66%) pts progressed. Median PFS and OS was 3.7m (95% CI 2.52-9.54) and 11.2m (95% CI 6.3-NR), respectively. ORR was 22.4%. A non-significant trend towards longer PFS was observed between LDH

Conclusions

Our cohort demonstrated similar survival outcomes to KEYNOTE-010. Baseline NLR, dNLR, LDH, PD-L1 TPS and LIPI score were not significantly prognostic of survival.

Clinical trial identification

Legal entity responsible for the study

The Christie NHS Foundation Trust, Manchester, United Kingdom.

Funding

The Christie NHS Foundation Trust, Manchester, United Kingdom.

Editorial Acknowledgement

Disclosure

R. Califano: Honoraria for consultancy and advisory boards: MSD. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.